DOI: 10.25881/BPNMSC.2020.60.92.026

Авторы

Гительзон Д.Г.1, 2, Файбушевич А.Г.1, Максимкин Д.А.1, Веретник Г.И.1, Васильев А.Э.2, Гительзон Е.А.1, Данишян К.И.2

1 ФГАОУ ВО Российский Университет Дружбы Народов, Москва

2 ФГБУ НМИЦ гематологии Минздрава России, Москва

Аннотация

Стентирование коронарных артерий является распространенным и эффективным эндоваскулярным методом лечения различных форм ишемической болезни сердца (ИБС). Для профилактики тромбоза стента (ТС) до и продолжительное время после стентирования в большинстве случаев назначается двойная антитромботическая терапия (ДАТ). Однако крайне редко проводится контроль эффективности ДАТ. Несмотря на то, что среди всех пациентов с ИБС после стентирования коронарных артерий, в 0,6–2% случаев в течение года возникает ТС с высокой летальностью. За время работы мы встретили несколько случаев острого ТС. Приводим клиническое наблюдение.

Ключевые слова: агрегация тромбоцитов; антитромботическая терапия; стентирование коронарных артерий; ишемическая болезнь сердца.

Список литературы

1. Добровольский А.Б., Руда М.Я., Сироткина О.В., и др. Резистентность к клопидогрелу у больных острым коронарным синдромом // Терапевтический архив. — 2010. — Т.82. — №8. — С. 14–20. [Frolova NS, Shakhnovich RM, Sirotkina OV, et al. Clopidogrel resistance in patients with acute coronary syndrome. Ter Arkh. 2010;82(8):14–20. (In Russ).]

2. Мирзаев К.Б., Андреев Д.А., Сычев Д.А. Оценка агрегации тромбоцитов в клинической практике // Рациональная фармакотерапия в кардиологии. — 2015. — Т.11. — №1. — С. 85–91. [Mirzaev KB, Andreev DA, Sychev DA. Evaluation of platelet aggregation in clinical practice. Rational pharmacotherapy in cardiology. 2015;11(1):85–91. (In Russ).] doi: 10.20996/1819-6446-2015-11-1-85-91.

3. Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35(4):209–215. doi: 10.1093/eurheartj/eht375.

4. Asher E, Abu-Much A, Goldenberg I, et al. Incidence and clinical features of early stent thrombosis in the era of new P2Y12 inhibitors (PLATIS-2). PLoS One. 2016;11(6):e0157437. doi: 10.1371/journal.pone.0157437.

5. Brodie B, Pokharel Y, Garg A, et al. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2012;5(10):1043–1051. doi: 10.1016/j.jcin.2012.06.013.

6. Buchanan GL, Basavarajaiah S, Chieffo A. Stent thrombosis: incidence, predictors and new technologies. Thrombosis. 2012;2012:956–962. doi: 10.1155/2012/956962.

7. Byrne RA, Serruys PW, Baumbach A, et al. Report of a European Society of Cardiology — European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J. 2015; 36(38):2608–2620. doi: 10.1093/eurheartj/ehv203.

8. Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306 (16):1765–1774. doi: 10.1001/jama.2011.1529.

9. Centemero MP, Stadler JR. Stent thrombosis: an overview expert review. Expert Rev Cardiovasc Ther. 2012;10(5):599–615. doi: 10.1586/erc.12.38.

10. Chen W, Wu Y, Hu Y. Early (≤ 30 Days), late (31-360 Days) and very late (> 360 Days) stent thrombosis in patients with insulin-treated versus non-insulin-treated type 2 diabetes mellitus: a meta-analysis. Diabetes Ther. 2018;9(3):1113–1124. doi: 10.1007/s13300-018-0425-1.

11. D’Ascenzo F, Bollati M, Clementi F, et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013;167(2):575–584. doi: 10.1016/j.ijcard.2012.01.080.

12. Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e89S–e119S. doi: 10.1378/chest.11-2293.

13. Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56(17):1357–1365. doi: 10.1016/j.jacc.2010.07.016.

14. who.int [Internet]. Information bulletin of WHO. Top 10 causes of death worldwide [updated 2018 May 24; cited 2019 Nov 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

15. Kubo S, Kadota K, Ichinohe T, et al. Comparison of long-term outcome after percutaneous coronary intervention for stent thrombosis between early, late and very late stent thrombosis. Circ J. 2014;78(1):101–109. doi: 10.1253/circj.cj-13-0780.

16. Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35(31):2083–2093. doi: 10.1093/eurheartj/ehu160.

17. Motovska Z, Knot J, Widimsky P. Stent thrombosis — risk assessment and prevention. Cardiovasc Ther. 2010;28(5):e92–100. doi: 10.1111/j.1755-5922.2010.00186.x.

18. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32(23): 2922–2932. doi: 10.1093/eurheartj/ehr373.

19. Sabouret P, Rushton-Smith SK, Kerneis M, et al. Dual antiplatelet therapy: optimal timing, management and duration. Eur Heart J Cardiovasc Pharmacother. 2015;1(3):198–204. doi: 10.1093/ehjcvp/pvv015.

20. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334(17):1084–1089. doi: 10.1056/NEJM199604253341702.

21. Shah R, Rashid A, Hwang I, et al. Meta-analysis of the relative efficacy and safety of oral P2Y12 inhibitors in patients with acute coronary syndrome. Am J Cardiol. 2017;119(11):1723–1728. doi: 10.1016/j.amjcard.2017.03.011.

22. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicenter registry study. Lancet. 2013;382(9892):614–623. doi: 10.1016/S0140-6736(13)61170-8.

23. Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6 (12):1267–1274. doi: 10.1016/j.jcin.2013.06.015.

24. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–260. doi: 10.1093/ eurheartj/ehx419.

25. van Werkum JW, Heestermans AA, de Korte FI, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation. 2009;119(6):828–834. doi: 10.1161/CIRCULATIONAHA.108.799403.

26. Varenhorst C, Lindholm M, Sarno G, et al. Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. Clin Res Cardiol. 2018; 107(9):816–823. doi: 10.1007/s00392-018-1252-0.